What Is ENBREL?

ENBREL is an anti-TNF therapy indicated for the treatment of adult chronic moderate to severe plaque psoriasis and for psoriatic arthritis.

Clinical Experience

Expand Chart
Evaluated in clinical studies over the past 19 years in rheumatoid arthritis (RA)1*
More than 14 years of postmarketing experience since approval for moderate to severe RA in 19981
  • 8 years of postmarketing experience in moderate to severe plaque psoriasis1
  • ENBREL is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL can be initiated in combination with methotrexate (MTX) or used alone
  • 10 years of clinical experience in psoriatic arthritis1
  • 8 years of postmarketing experience in moderate to severe plaque psoriasis1
  • ENBREL is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL can be initiated in combination with methotrexate (MTX) or used alone
  • 10 years of continuous safety data in moderate to severe rheumatoid arthritis (RA)1,2

*Initial clinical research in RA patients began in 1993. ENBREL approved for adult chronic moderate to severe plaque psoriasis in 2004.

For a description of the full FDA-approved ENBREL indications, click here.

ENBREL binds reversibly to tumor necrosis factor (TNF)4

How ENBREL Works

Although the exact cause of psoriatic diseases is unknown, elevated levels of TNF are found in the tissues and fluids of patients with psoriatic arthritis and plaque psoriasis.3,4

In psoriasis, the chronic T-cell–dependent inflammatory process occurring in the skin is mediated by TNF and other inflammatory cytokines. As a result of this inflammatory process, epidermal thickening occurs and the lesions covered by white, silvery scales typical of plaque psoriasis appear.5,6

ENBREL was designed to bind specifically to TNF and block its interaction with cell surface TNF receptors, thereby modulating the biological responses induced or regulated by TNF.

Because ENBREL suppresses the immune system, it increases the risk of infections.

There have been reported postmarketing cases of new or worsening psoriasis.


 
INDICATIONS

ENBREL is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL can be initiated in combination with methotrexate (MTX) or used alone.

ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients ages 2 and older.

ENBREL is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis. ENBREL can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone.

ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.

ENBREL is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Supportive data

Moderate to Severe Plaque Psoriasis
In medical studies, nearly half of patients saw 75% skin clearance in their moderate to severe plaque psoriasis in 3 months with ENBREL. Overall, 3 out of 4 patients saw 50% skin clearance in 3 months. ENBREL can work fast; many patients saw improvement within 2 months. Your results may vary.

Psoriatic Arthritis
In a medical study, ENBREL was shown to be effective in about 50% of psoriatic arthritis patients who used it at 6 months. Clinical responses were apparent at the time of the first visit (4 weeks) and were maintained through 6 months of therapy.

Subcutaneous Administration Options

ENBREL provides you
and your patients the
flexibility of multiple
administration options.

View demonstrations arrow

Evelyn was embarrassed about her plaques and would cover up before going out in public.

Worried that her condition was not improving, Evelyn decided to take action.

"ENBREL helped me, I am proof that this drug can work."
Home
Close